aUnidad de Enfermedades Infecciosas, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofia, Cordoba bUnidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville cUnidad de Inmunogenética, Faculty of Sciences, Universidad de Jaén, Jaén, Spain.
AIDS. 2013 Jul 31;27(12):1941-7. doi: 10.1097/QAD.0b013e328360ea1e.
To evaluate the IL28B effect on hepatitis C virus (HCV) decline during first weeks of treatment according to HCV-1 subtypes.
Patients coinfected with HIV/HCV genotype 1 and naive to peginterferon-alpha-2a and ribavirin (Peg-IFN-alpha-2a/RBV) were included. Plasma HCV-RNA was measured at baseline, and then at weeks 1, 2, and 4. HCV-1 subtype (1a or 1b) was determined. HCV viral decline was analyzed according to HCV-1 subtype between baseline and week 1, week 2 and week 4 of treatment. Additionally, we analyzed the effect of the IL28B (rs12979860) genotype on HCV viral decline with HCV-1a and HCV-1b genotype patients (CC versus non-CC).
Two hundred and six patients were included in the study, of whom 113 (54.8%) and 93 (45.2%) were infected by HCV-1a and 1b genotypes, respectively. No differences were found between HCV-1 subtypes in terms of HCV viral decline or rapid virological response rate. The effect of the IL28B-CC genotype on HCV viral decline was observed only among patients infected with HCV-1b at all time points analyzed (week 1: CC 1.53 ± 0.33, non-CC 0.27 ± 0.24, P <0.001; week 2: CC 1.81 ± 0.39, non-CC 0.74 ± 0.39, P = 0.002; week 4: CC 2.97 ± 0.53, non-CC 1.2 ± 0.61, P < 0.001).
Our study suggests that the effect associated with the impact of the IL28B-CC genotype on HCV decline during the first weeks of treatment with Peg-IFN-alpha-2a/RBV differs according to HCV-1 subtype and may be limited to HCV-1b patients.
根据 HCV-1 亚型评估 IL28B 在治疗最初几周内对 HCV 下降的影响。
纳入 HIV/HCV 基因型 1 合并感染且对聚乙二醇干扰素-α-2a 和利巴韦林（Peg-IFN-α-2a/RBV）无应答的患者。基线时和治疗第 1、2、4 周时检测血浆 HCV-RNA。确定 HCV-1 亚型（1a 或 1b）。根据基线至第 1 周、第 2 周至第 4 周治疗期间的 HCV-1 亚型分析 HCV 病毒下降情况。此外，我们分析了 IL28B（rs12979860）基因型对 HCV-1a 和 HCV-1b 基因型患者（CC 与非-CC）HCV 病毒下降的影响。
共纳入 206 例患者，其中 113 例（54.8%）和 93 例（45.2%）分别感染 HCV-1a 和 1b 基因型。在 HCV 病毒下降率或快速病毒学应答率方面，HCV-1 亚型之间无差异。IL28B-CC 基因型对 HCV 病毒下降的影响仅在所有分析时间点（第 1 周：CC 1.53±0.33，非-CC 0.27±0.24，P<0.001；第 2 周：CC 1.81±0.39，非-CC 0.74±0.39，P=0.002；第 4 周：CC 2.97±0.53，非-CC 1.2±0.61，P<0.001）感染 HCV-1b 的患者中观察到。
本研究表明，在接受 Peg-IFN-α-2a/RBV 治疗的最初几周内，IL28B-CC 基因型对 HCV 下降的影响与 HCV-1 亚型相关，且可能仅限于 HCV-1b 患者。
